Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

References

• WeidenPJEPS profiles: the atypical antipsychotics are not all the sameJ Psychiatr Pract200713132417242588
   PubMedGoogle Scholar
• KaneJMWoernerMWeinholdPWegnerJKinonBBorensteinMIncidence of tardive dyskinesia: five-year data from a prospective studyPsychopharmacol Bull1984203873896473637
   PubMedGoogle Scholar
• GlazerWMMorgensternHDoucetteJTPredicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medicationsJ Clin Psychiatry1993541331398098030
   PubMed Web of Science ®Google Scholar
• JesteDVLacroJPPalmerBRockwellEHarrisMJCaligiuriMPIncidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patientsAm J Psychiatry19991563093119989570
   PubMed Web of Science ®Google Scholar
• BeasleyCMJrSangerTSatterleeWTollefsonGTranPHamiltonSOlanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialPsychopharmacology19961241591678935812
   PubMed Web of Science ®Google Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry200416141442514992963
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• MillerDDCaroffSNDavisSMExtrapyramidal side-effects of antipsychotics in a randomised trialBr J Psychiatry200819327928818827289
   PubMed Web of Science ®Google Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• TollefsonGDBeasleyCMJrTranPVOlanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trialAm J Psychiatry19971544574659090331
   PubMed Web of Science ®Google Scholar
• GuyWAbnormal involuntary movement scale (AIMS)ECDEU Assessment Manual for Psychopharmacology RevisedRockville, MDAlcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health1976
   Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• TunisSLFariesDENyhuisAWKinonBJAscher-SvanumHAquilaRCost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trialValue Health20069778916626411
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edWashington, DCAmerican Psychiatric Association1994
   Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
   PubMed Web of Science ®Google Scholar
• DavisJMChenNThe effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trialsJ Clin Psychiatry20016275777111816864
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care1992304734831593914
   PubMed Web of Science ®Google Scholar
• WareJEJrKosinskiMBaylissMSMcHorneyCARogersWHRaczekAComparison of methods for the scoring and statistical analysis of SF-36 Health Profile and Summary Measures: summary of results from the Medical Outcomes StudyMed Care199533S4 SupplAS264AS2797723455
   PubMedGoogle Scholar
• CarlsonCDCavazzoniPABergPHWeiHBeasleyCMKaneJMAn integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapineJ Clin Psychiatry20036489890612927004
   PubMed Web of Science ®Google Scholar
• SchoolerNRKaneJMResearch diagnosis for tardive dyskinesiaArch Gen Psychiatry1982394864876121550
   PubMed Web of Science ®Google Scholar
• KinonBJStaufferVLKollack-WalkerSChenLSniadeckiJOlanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophreniaJ Clin Psychopharmacol20082860160719011427
   PubMed Web of Science ®Google Scholar
• MeltzerHYCucchiaroJSilvaRLurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled studyAm J Psychiatry201116895796721676992
   PubMed Web of Science ®Google Scholar
• KinonBJKollack-WalkerSStaufferVLiu-SeifertHReduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidolJ Clin Psychopharmacol20123242042222561475
   PubMed Web of Science ®Google Scholar
• KinonBJKaneJMChakosMMunneRPossible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effectsPsychopharmacol Bull1993293653697907184
   PubMedGoogle Scholar
• LevinsonDFSimpsonGMSinghHFluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatmentArch Gen Psychiatry1990477617682378547
   PubMed Web of Science ®Google Scholar
• KinonBJKaneJMJohnsCTreatment of neuroleptic-resistant schizophrenic relapsePsychopharmacol Bull1993293093147904762
   PubMedGoogle Scholar
• EmilssonMBerndtssonILotvallJThe influence of personality traits and beliefs about medicines on adherence to asthma treatmentPrim Care Respir201120141147
   PubMedGoogle Scholar
• CaseMStaufferVLAscher-SvanumHThe heterogeneity of antipsychotic response in the treatment of schizophreniaPsychol Med2011411291130020925971
   PubMed Web of Science ®Google Scholar
• RabinowitzJHarveyPDEerdekensMDavidsonMPremorbid functioning and treatment response in recent-onset schizophreniaBr J Psychiatry2006189313516816303
   PubMed Web of Science ®Google Scholar
• ChakosMHMayerhoffDILoebelADIncidence and correlates of acute extrapyramidal symptoms in first episode of schizophreniaPsychopharmacol Bull19922881861609046
   PubMedGoogle Scholar
• AguilarEJKeshavanMSMartinez-QuilesMDPredictors of acute dystonia in first-episode psychotic patientsAm J Psychiatry1994151181918217977894
   PubMed Web of Science ®Google Scholar
• FreemantleNDrummondMShould clinical trials with concurrent economic analyses be blinded?JAMA199727763648980212
   PubMed Web of Science ®Google Scholar
• TunisSLJohnstoneBMKinonBJBarberBLBrowneRADesigning naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapiesValue Health2000323224216464187
   PubMedGoogle Scholar
• AddingtonDEPantelisCDineenMBenattiaIRomanoSJEfficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trialJ Clin Psychiatry2004651624163315641867
   PubMed Web of Science ®Google Scholar